Pulse Biosciences, Inc. (NASDAQ: PLSE) reported Q3 EPS of ($0.64).

“We’re pleased with the continued and significant progress we’ve made and are making towards bringing our NPS platform closer to commercialization,” said Darrin Uecker, Pulse Biosciences’ President and Chief Executive Officer. “Our data continues to demonstrate safety and efficacy allowing us the opportunity to move forward with our plans to target the cash paying aesthetic dermatology market while we continue to make progress in longer-term opportunities.”

For earnings history and earnings-related data on Pulse Biosciences, Inc. (PLSE) click here.